Literature DB >> 1380886

Expression of human prostatic acid phosphatase activity and the growth of prostate carcinoma cells.

M F Lin1, J DaVolio, R Garcia-Arenas.   

Abstract

Human prostatic acid phosphatase (PAcP) is a tissue-specific differentiation antigen and is the major phosphotyrosyl (p-tyr) protein phosphatase in normal differentiated prostate epithelial cells. In prostate carcinomas, cellular PAcP has a low expression. We examined the expression of cellular PAcP activity and its correlation with cell growth that may lead us to understand the role of tyrosine phosphorylation in human prostate cells. LNCaP cells, which expressed the highest cellular PAcP activity, had the slowest growth rate and the lowest p-tyr level among three human prostate carcinoma cell lines: LNCaP, DU145, and PC-3. This inverse correlation was further examined in LNCaP cells, since these cells remain hormone-sensitive. Androgen, a classical stimulator of prostate cells, stimulated the growth of LNCaP cells while cellular PAcP activity decreased and p-tyr levels increased. This phenomenon was also observed when cells were treated with epidermal growth factor and fetal bovine serum. Both epidermal growth factor and fetal bovine serum stimulated the growth of LNCaP cells whereas cellular PAcP activity decreased. Furthermore, when cell growth was arrested at low temperatures (23 degrees C), cellular PAcP activity was elevated. To establish the relationship of cellular PAcP activity with cell growth rate, we transfected a complementary DNA encoding the full length PAcP protein into another human prostate carcinoma line, PC-3, that lacks endogenous PAcP. Two stable transfectants, designated PC-18 and PC-416 cells, were obtained and shown to express PAcP mRNA transcribed from the transfected complementary DNA. The expression of PAcP activity in PC-416 cells, but not PC-18 cells, was associated with a lower p-tyr level and a slower growth rate than control cells transfected with the expression vector alone. In conclusion, in LNCaP cells, the stimulated cell growth is associated with an increased p-tyr level and a decreased cellular PAcP activity. In PAcP complementary DNA-transfected PC-416 cells, the low level of p-tyr corresponds to a slow growth rate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380886

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Expression of receptor protein tyrosine phosphatase alpha mRNA in human prostate cancer cell lines.

Authors:  S Zelivianski; J Dean; D Madhavan; F F Lin; M F Lin
Journal:  Mol Cell Biochem       Date:  2000-05       Impact factor: 3.396

2.  p66Shc longevity protein regulates the proliferation of human ovarian cancer cells.

Authors:  Sakthivel Muniyan; Yu-Wei Chou; Te-Jung Tsai; Paul Thomes; Suresh Veeramani; Benedict B Benigno; L DeEtte Walker; John F McDonald; Shafiq A Khan; Fen-Fen Lin; Subodh M Lele; Ming-Fong Lin
Journal:  Mol Carcinog       Date:  2014-01-07       Impact factor: 4.784

3.  Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone-releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation.

Authors:  I Sasagawa; T Nakada; Y Kubota; T Sawamura; K Izumiya
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

4.  The enhancement by pervanadate of tyrosine phosphorylation on prostatic proteins occurs through the inhibition of membrane-associated tyrosine phosphatases.

Authors:  M Boissonneault; A Chapdelaine; S Chevalier
Journal:  Mol Cell Biochem       Date:  1995 Dec 6-20       Impact factor: 3.396

5.  Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells.

Authors:  Yu-Wei Chou; Nagendra K Chaturvedi; Shougiang Ouyang; Fen-Fen Lin; Dharam Kaushik; Jue Wang; Isaac Kim; Ming-Fong Lin
Journal:  Cancer Lett       Date:  2011-07-22       Impact factor: 8.679

6.  Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.

Authors:  P Castelo-Branco; B J Passer; J S Buhrman; S Antoszczyk; M Marinelli; C Zaupa; S D Rabkin; R L Martuza
Journal:  Gene Ther       Date:  2010-03-11       Impact factor: 5.250

7.  Regulation of citrate metabolism by androgen in the LNCaP human prostate carcinoma cell line.

Authors:  R B Franklin; H H Juang; J Zou; L C Costello
Journal:  Endocrine       Date:  1995-08       Impact factor: 3.633

8.  Transcriptional activation of the human prostatic acid phosphatase gene by NF-kappaB via a novel hexanucleotide-binding site.

Authors:  Stanislav Zelivianski; Richard Glowacki; Ming-Fong Lin
Journal:  Nucleic Acids Res       Date:  2004-07-07       Impact factor: 16.971

Review 9.  Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor.

Authors:  Sakthivel Muniyan; Matthew A Ingersoll; Surinder K Batra; Ming-Fong Lin
Journal:  Biochim Biophys Acta       Date:  2014-04-18

10.  Prostatic acid phosphatase is an ectonucleotidase and suppresses pain by generating adenosine.

Authors:  Mark J Zylka; Nathaniel A Sowa; Bonnie Taylor-Blake; Margaret A Twomey; Annakaisa Herrala; Vootele Voikar; Pirkko Vihko
Journal:  Neuron       Date:  2008-10-09       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.